Josias Pontes - 03 Jan 2022 Form 4 Insider Report for Sigilon Therapeutics, Inc.

Role
VP, HEAD OF FINANCE
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Jan 2022
Net transactions value
+$196,950
Form type
4
Filing time
04 Jan 2022, 15:16:03 UTC
Previous filing
04 Oct 2021
Next filing
22 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $196,950 +65,000 $3.03* 65,000 03 Jan 2022 Common Stock 65,000 $3.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 30% on January 3, 2023 and 70% on January 3, 2024.